Alzheimer’s Disease Awareness Month

 Beta-amyloid protein disrupting nerve cells function in a brain with Alzheimer’s disease

In November, we are spreading awareness about the devastating Alzheimer’s Disease. Alzheimer’s Disease often creeps up unnoticeably with symptoms worsening gradually over time. It mostly affects the older population; however, it can also start as early as in the person’s 40s or 50s. AD is the most widespread form of Dementia impacting both short- and long-term memory, thinking ability, mood and behavior.

Medication and therapy are available to treat some of the symptoms and to slow down cognitive decline. Even though no cure exists for AD, the research is ongoing actively.

GCT is a CNS & Neurology focused CRO with Dr. Jeffrey Apter, a Key Opinion Leader (KOL) in Alzheimer’s Disease as the president of the company. Please reach out to us at to find out about our experience in AD trials and / or to request a quote.

Subscribe to our mailing list

Marketing Permissions

Please select all the ways you would like to hear from Global Clinical Trials (GCT):

You can unsubscribe at any time by clicking the link in the footer of our emails. Please see our Privacy Policy. We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.


GCT is a CRO experienced in performing clinical research in the USA, Europe, Russia and India.

We are a full-service clinical development provider, offering feasibility analysis, regulatory submission, site selection, project management, monitoring, data management, logistics, and more.

Go social with us

Follow us on social networks:

Privacy policy, Terms of service, Site map, Employees login



© 2001—2021 Global Clinical Trials, LLC

All rights reserved.